NanoViricides Inc. (NNVC)

[changes_iv]

Nanomachines: How Viruses Work, and How We Can Stop Them

Watch this 44 minutes long great lecture from Carolyn Bertozzi, director of Berkeley Lab's Molecular Foundry, a colleague of Dr. Eva Harris, Professor of Public Health and Infectious Diseases at the University of California, Berkeley. Prof. Harris found that the special laboratory mouse strain AG129 infected with a dengue virus in a lethal challenge ADE-simulation protocol, when left untreated, suffered a 100% fatality rate. In contrast, in the same study, animals treated with NanoViricides' DengueCide achieved an unprecedented 50% survival rate.

DengueCide is a nanoviricide® that has shown very high effectiveness in animal models of dengue virus infection and also in cell culture studies of dengue virus infection. These animal studies as well as cell culture studies were conducted in the laboratory of Dr. Eva Harris, Professor of Public Health and Infectious Diseases at the University of California, Berkeley.

Dengue and dengue hemorrhagic fever have been designated as orphan drug status eligible diseases in the USA. Orphan Drug designation enables several benefits to promote drug development that include tax credits and an extended exclusive marketing period upon drug approval. These benefits provide significant financial incentives for developing orphan drugs. However, there can be no assurance that DengueCide will be granted an orphan drug designation. *** FDA has since designated DengueCide as Orphan Drug ***

In addition to the incentives related to orphan drug status, the Company may be eligible to receive a Priority Review Voucher (PRV) in the USA, upon approval of a drug against dengue viruses. A PRV can be applied by the Company to another drug candidate to obtain a “priority review” to speed up the regulatory process for that other drug. A PRV can also potentially be sold to another pharmaceutical company to obtain an immediate financial benefit. The value of a PRV has been variously estimated to be between $200M to $600M for such transactions.

There is currently neither an effective drug treatment nor a vaccine for dengue virus infection. Tremendous efforts have been made for dengue vaccine development but, to date, no vaccine candidate has succeeded in clinical trials towards approval.

source: http://www.fool.com/investing/businesswire/2013/06/10/nanoviricides-submits-denguecide-orphan-drug-desig.aspx

http://youtu.be/dhE2LJTT0-o

All Allan: NNVC - Update
http://allallan.blogspot.com/2009/07/nnvc-update.html